| Literature DB >> 27084016 |
Nhung T Nguyen1, Hoa M Nguyen2, Cuong V Nguyen2, Trung V Nguyen2,3, Men T Nguyen4, Hieu Q Thai4, Mai H Ho4, Guy Thwaites2,5, Hoa T Ngo2,5, Stephen Baker2,5, Juan Carrique-Mas2,5.
Abstract
UNLABELLED: Antimicrobial resistance (AMR) is a global health problem, and emerging semi-intensive farming systems in Southeast Asia are major contributors to the AMR burden. We accessed 12 pig and chicken farms at key stages of production in Tien Giang Province, Vietnam, to measure antimicrobial usage and to investigate the prevalence of AMR to five critical antimicrobials (β-lactams, third-generation cephalosporins, quinolones, aminoglycosides, and polymyxins) and their corresponding molecular mechanisms among 180 Escherichia coli isolates. Overall, 94.7 mg (interquartile range [IQR], 65.3 to 151.1) and 563.6 mg (IQR, 398.9 to 943.6) of antimicrobials was used to produce 1 kg (live weight) of chicken and pig, respectively. A median of 3 (out of 8) critical antimicrobials were used on pig farms. E. coli isolates exhibited a high prevalence of resistance to ampicillin (97.8% and 94.4% for chickens and pigs, respectively), ciprofloxacin (73.3% and 21.1%), gentamicin (42.2% and 35.6%), and colistin (22.2% and 24.4%). The prevalence of a recently discovered colistin resistance gene, mcr-1, was 19 to 22% and had strong agreement with phenotypic colistin resistance. We conducted plasmid conjugation experiments with 37 mcr-1 gene-positive E. coli isolates and successfully observed transfer of the gene in 54.0% of isolates through a plasmid of approximately 63 kb, consistent with one recently identified in China. We found no significant correlation between total use of antimicrobials at the farm level and AMR. These data provide additional insight into the role of mcr-1 in colistin resistance on farms and outline the dynamics of phenotypic and genotypic AMR in semi-intensive farming systems in Vietnam. IMPORTANCE: Our study provides accurate baseline information on levels of antimicrobial use, as well as on the dynamics of phenotypic and genotypic resistance for antimicrobials of critical importance among E. coli over the different stages of production in emerging pig and poultry production systems in Vietnam. E. coli isolates showed a high prevalence of resistance (>20%) to critically important antimicrobials, such as colistin, ciprofloxacin, and gentamicin. The underlying genetic mechanisms identified for colistin (the mcr-1 gene) and quinolone (gyrA gene mutations) are likely to play a major role in AMR to those compounds. Conjugation experiments led to the identification of a 63-kb plasmid, similar to one recently identified in China, as the potential carrier of the mcr-1 gene. These results should encourage greater restrictions of such antimicrobials in Southeast Asian farming systems.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27084016 PMCID: PMC4907207 DOI: 10.1128/AEM.00337-16
Source DB: PubMed Journal: Appl Environ Microbiol ISSN: 0099-2240 Impact factor: 5.005
Amounts of antimicrobials present in commercial feeds and estimated consumption of in-feed antimicrobials on each of the 9 farms investigated
| Product no. | Period of use | Antimicrobial | Concn of antimicrobial in feed (mg/kg live wt) | Estimated consumption of in-feed antimicrobials | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chicken farms | Pig farms | |||||||||||
| C1 | C3 | C4 | C5 | C6 | P2 | P3 | P5 | P6 | ||||
| 1 | 1 and 2 | Avilamycin OR | 10 | 28.5 | 28.5 | 28.5 | 57.0 | 28.5 | ||||
| Enramycin | 10 | 28.5 | 28.5 | 28.5 | 57.0 | 28.5 | ||||||
| 2 | 1 and 2 | Enramycin | 10 | 28.5 | 28.5 | 28.5 | ||||||
| 3 | 1 and 2 | Colistin | 180 | 702.0 | ||||||||
| Florfenicol OR | 30 | 117.0 | ||||||||||
| Kitazamycin OR | 110 | 429.0 | ||||||||||
| Tiamulin OR | 120 | 468.0 | ||||||||||
| Amoxicillin | 150 | 585.0 | ||||||||||
| 4 | 1 and 2 | Avilamycin OR | 10 | 39.0 | ||||||||
| Kitasamycin OR | 110 | 429.0 | ||||||||||
| Tiamulin | 120 | 468.0 | ||||||||||
| 5 | 1 and 2 | Tylosin OR | 40 | 156.0 | ||||||||
| Enramycin OR | 20 | 78.0 | ||||||||||
| Colistin | 150 | 585.0 | ||||||||||
| 6 | 1 and 2 | Chlortetracycline OR | 50 | 195.0 | ||||||||
| Neomycin | 65 | 253.5 | ||||||||||
| Enramycin OR | 20 | 78.0 | ||||||||||
| Virginiamycin | 10 | 39.0 | ||||||||||
| 7 | 1 and 2 | Chlortetracycline OR | 50 | 95.0 | ||||||||
| Virginiamycin OR | 10 | 39.0 | ||||||||||
| Lincomycin | 20 | 78.0 | ||||||||||
| 8 | 1 and 2 | Chlortetracycline OR | 100 | 390.0 | ||||||||
| Bacitracin | 50 | 195.0 | ||||||||||
| 9 | 1 | Tylosin OR | 40 | 156.0 | ||||||||
| Enramycin OR | 20 | 78.0 | ||||||||||
| Amoxicillin | 300 | 1,170.0 | ||||||||||
| 10 | 1 | Tylosin OR | 40 | 156.0 | ||||||||
| Enramycin OR | 20 | 78.0 | ||||||||||
| Colistin | 150 | 585.0 | ||||||||||
| 11 | 1 and 2 | Chlortetracycline OR | 50 | 195.0 | ||||||||
| Lincomycin OR | 20 | 78.0 | ||||||||||
| Virginiamycin OR | 10 | 39.0 | ||||||||||
| Enramycin | 20 | 78.0 | ||||||||||
Period 1, early phase of production; period 2, late phase of production.
Details of antimicrobials in feed were not available for farms C2, P1, and P4.
Antimicrobial considered to be critically important for human medicine according to WHO criteria.
Amounts of antimicrobials administered for prophylactic and therapeutic purposes on chicken and pig farms
| Antimicrobial class | Antimicrobial agent | Amt administered (mg/kg live wt) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chicken farms | Pig farms | ||||||||||||
| C1 | C2 | C3 | C4 | C5 | C6 | P1 | P2 | P3 | P4 | P5 | P6 | ||
| Aminoglycoside | Neomycin | 11.7 | |||||||||||
| Kanamycin | 11.1 | ||||||||||||
| Gentamicin | 26.7 | 16.2 | 6.7 | 5.9 | 14.3 | ||||||||
| β-Lactam | Amoxicillin | 40.0 | 13.3 | 25.1 | 22.3 | ||||||||
| Ampicillin | 17.8 | ||||||||||||
| Cephalosporin | Cephalexin | 5.6 | |||||||||||
| Ceftiofur | 9.5 | ||||||||||||
| Macrolide | Tylosin | 23.0 | 5.6 | 12.2 | |||||||||
| Tilmicosin | 6.8 | 10.0 | |||||||||||
| Spiramycin | 12.5 | 23.8 | |||||||||||
| Phenicol | Chloramphenicol | 6.5 | |||||||||||
| Florfenicol | 11.3 | 16.7 | 11.1 | ||||||||||
| Polypeptide | Colistin | 5.3 | 1.8 | 1.4 | 3.3 | ||||||||
| Fluoroquinolone | Enrofloxacin | 66.7 | 11.1 | 23.3 | 19.1 | 40.6 | |||||||
| Norfloxacin | 53.3 | 1.8 | 4.9 | ||||||||||
| Tetracycline | Doxycycline | 46.0 | 5.6 | 8.3 | 26.7 | 5.6 | 5.5 | ||||||
| Oxytetracycline | 11.7 | ||||||||||||
| Total | 69.0 | 23.7 | 35.0 | 112.0 | 121.8 | 27.9 | 23.4 | 47.4 | 85.4 | 30.4 | 44.8 | 86.9 | |
Each line represents one antimicrobial component.
Antimicrobial considered to be critically important for human medicine according to WHO criteria.
FIG 1Prevalence of AMR among 180 E. coli isolates (30 isolates/visit/host species) from 12 farms in Tien Giang, Vietnam (2013–2014). The error bars indicate 95% confidence intervals. AMP, ampicillin; CAZ, ceftazidime; CIP, ciprofloxacin; CN, gentamicin; CT, colistin.
FIG 2Prevalence of antimicrobial resistance genes among 180 E. coli isolates recovered from 12 farms in Tien Giang, Vietnam (2013–2014). *, phenotypic prevalence of antimicrobial resistance. (1), single mutation; (2), double mutation. The error bars indicate the 95% CI.
Estimation of the level of agreement between resistance phenotypes and genotypes in E. coli isolates
| Antimicrobial | Gene(s) carried | Chicken | Pig | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| κ | a | b | c | d | κ | a | b | c | d | ||||
| Ciprofloxacin | 0.07 | 20 | 48 | 4 | 18 | 0.150 | −0.07 | 2 | 17 | 8 | 63 | 0.835 | |
| NC | 0 | 66 | 0 | 24 | NC | NC | 0 | 19 | 0 | 71 | NC | ||
| 0.02 | 19 | 50 | 5 | 16 | 0.368 | 0.12 | 6 | 13 | 33 | 38 | 0.127 | ||
| NC | 0 | 66 | 0 | 24 | NC | 0.15 | 2 | 17 | 0 | 71 | 0.055 | ||
| NC | 0 | 66 | 0 | 24 | NC | NC | 0 | 19 | 0 | 71 | NC | ||
| 0.01 | 22 | 44 | 8 | 16 | 0.50 | 0.24 | 7 | 12 | 10 | 61 | 0.012 | ||
| 0.43 | 39 | 27 | 0 | 24 | <0.001 | 0.73 | 12 | 7 | 0 | 71 | <0.001 | ||
| Gentamicin | 0.33 | 28 | 11 | 18 | 33 | <0.001 | 0.13 | 29 | 3 | 43 | 15 | 0.030 | |
| 0.26 | 26 | 13 | 17 | 34 | <0.001 | 0.19 | 10 | 22 | 8 | 50 | 0.011 | ||
| Colistin | 1.0 | 20 | 0 | 0 | 70 | <0.001 | 0.84 | 17 | 5 | 0 | 68 | <0.001 | |
a, positive genotype, positive phenotype; b, negative genotype, positive phenotype; c, positive genotype, negative phenotype; d, negative genotype, negative phenotype; NC, not calculated.
Associations between antimicrobial use and phenotypic and genotypic resistance among E. coli isolates from pigs
| Exposure | No. of farms using antimicrobial | Outcome | RR | 95% CI | |
|---|---|---|---|---|---|
| Exposure, antimicrobial use in period 1; outcome, resistance in second sampling | |||||
| Quinolones | 3 | CT | 11.0 | 2.71–44.66 | <0.001 |
| Cephalosporins | 1 | CT | 4.17 | 1.49–11.71 | 0.007 |
| Quinolones | 3 | CIP | 9.0 | 1.84–44.07 | 0.007 |
| Cephalosporins | 1 | CIP | 5.0 | 1.71–14.6 | 0.003 |
| Cephalosporins | 1 | 5.0 | 1.34–18.61 | 0.016 | |
| Quinolones | 3 | 4.50 | 1.23–16.46 | 0.023 | |
| Cephalosporins | 1 | 4.17 | 1.49–11.71 | 0.007 | |
| Exposure, antimicrobial use over whole production period; outcome, resistance in third sampling | |||||
| Tetracyclines | 1 | 10.0 | 2.71–36.96 | <0.001 | |
| β-Lactams | 2 | 5.0 | 1.02–24.52 | 0.047 | |
| Phenicols | 1 | 20.0 | 4.38–91.42 | <0.001 |
CIP, ciprofloxacin; CT, colistin.
Only significant (P < 0.05) risk ratios are presented.
CI, confidence interval.
Single or double mutation.